| abstract |
Isolated 7-[1-(4-chlorophenoxy)ethyl]-1,2,4-triazolo[1,5-a]pyrimidin-5-ol and pharmaceutically acceptable salts thereof in the form of individual enantiomers and mixtures thereof including the racemic mixture, pharmaceutical formulations containing this compound and the use of this compound in the treatment of seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, head injuries and haemorrhage, are described. |